TRIM44 overexpression has been reported in a diversity of tumors, including prostate cancer [8], gastric cancer [10], hepatocellular carcinoma (HCC) [11], intrahepatic cholangiocarcinoma [12], testicular germ cell tumor [13], lung cancer [9,14], and esophageal carcinoma [16,17]. Here, TRIM44 is linked to prostate carcinoma.